Meeting
2019 ASCO Annual Meeting
Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].
Authors
Jisun Kim
Department of Surgery, Asan Medical Center, Seoul, South Korea
Jisun Kim , Wonshik Han , Eun-Kyu Kim , Yongsik Jung , Hyun-Ah Kim , Soo Min Chae , Eun Sook Lee , Sei-Hyun Ahn , Tae Hyun Kim , Joon Jeong , Su Yun Choi , Seok Jin Nam , Nam-Sun Paik , Lee Su Kim , Gyungyub Gong , Jong Han Yu , So-Youn Jung , Hee Jeong Kim , Sung Gwe Ahn , Min Kyoon Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01589367
Citation
J Clin Oncol 37, 2019 (suppl; abstr 576)
DOI
10.1200/JCO.2019.37.15_suppl.576
Abstract #
576
Poster Bd #
68
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
First Author: Cristina Saura
First Author: Yeon Hee Park
Poster
2023 ASCO Annual Meeting
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
First Author: Matthew P. Goetz
First Author: Peter A. Fasching